Diabetes

WALTHAM, Mass. — Nipro Diagnostics and NeuroMetrix have teamed up to market a point-of-care test that is designed to evaluate such systemic neuropathies as diabetic peripheral neuropathy.

Nipro and NeuroMetrix said the NC-stat DPNCheck test, developed by NeuroMetrix, could offer a cost-effective approach to detecting and monitoring DPN, which affects more than half of people with diabetes and could lead to such conditions as foot ulcers and limb amputation.

The companies currently are evaluating opportunities for the NC-stat DPNCheck in retail medical clinics.

BUFFALO, N.Y. — A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

SILVER SPRING, Md. — The Food and Drug Administration on Thursday informed the public that continued use of a Type 2 diabetes treatment made by Takeda Pharmaceuticals for more than one year may be associated with an increased risk of bladder cancer.

INDIANAPOLIS — A new oral medication for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim has become available in pharmacies, the companies said Wednesday.

Lilly and BI announced the availability of Tradjenta (linagliptin) in chain and independent pharmacies around the country.

ALEXANDRIA, Va. — Novo Nordisk will serve as the national premier sponsor for the American Diabetes Association's annual fundraising walk in 2011 and 2012, the ADA announced.

BOSTON — Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

SILVER SPRING, Md. — The Food and Drug Administration has approved changes to the labels of several drugs made by Merck, the agency said Friday.

Merck’s Label Standardization Project includes the revision of 34 container labels for 16 drugs, all orally administered pills. These include the cardiovascular drugs Cozaar (losartan) and Hyzaar (losartan and hydrochlorothiazide), the diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin), the allergy and asthma drug Singulair (montelukast), the HIV drug Isentress (raltegravir) and others.

NEW YORK and WATERTOWN, Mass. — The Juvenile Diabetes Research Foundation and Selecta Biosciences have established a research collaboration to develop vaccines for Type 1 diabetes, also known as juvenile diabetes.

Through the collaboration, JDRF will provide "milestone-based financial support and expertise" to Selecta, which ultimately would apply its vaccine technology to create a vaccine that would halt or prevent the autoimmune response that causes Type 1 diabetes.